

CORRECTION


Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer

Michael T. Schweizer, Kathleen Haugk, Jožefa S. McKiernan, Roman Gulati, Heather H. Cheng, Jessica L. Maes, Ruth F. Dumpit, Peter S. Nelson, Bruce Montgomery, Jeannine S. McCune, Stephen R. Plymate, Evan Y. Yu

There is an error in the maximum plasma concentration of niclosamide reported in the “Results” section of the Abstract. The correct concentration range is: 35.7 to 182 ng/mL. This range is correctly reported in the “Pharmacokinetic results” section of the article as well as in Table 4.

Reference

1. Schweizer MT, Haugk K, McKiernan JS, Gulati R, Cheng HH, Maes JL, et al. (2018) A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. PLoS ONE 13(6): e0198389. <https://doi.org/10.1371/journal.pone.0198389> PMID: 29856824



OPEN ACCESS

Citation: Schweizer MT, Haugk K, McKiernan JS, Gulati R, Cheng HH, Maes JL, et al. (2018) Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. PLoS ONE 13(8): e0202709. <https://doi.org/10.1371/journal.pone.0202709>

Published: August 15, 2018

Copyright: © 2018 Schweizer et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.